Feb 13 (Reuters) - Johnson & Johnson JNJ.N on Thursday said it will discontinue a late-stage study of an experimental E.coli vaccine that it was developing in partnership with Sanofi SASY.PA.
The drugmaker said its decision was based on the recommendation of an independent committee that found the vaccine candidate may not be sufficiently effective.